Javascript must be enabled to continue!
Cutaneous lymphomas
View through CrossRef
SummaryPrimary cutaneous lymphomas are extranodal non‐Hodgkin lymphomas. They are classified into the two main groups of primary cutaneous T‐ and B‐cell lymphomas. Very rare cases are derived from NK or plasmacytoid dendritic cells. The annual incidence is 1/100,000. Two‐thirds of the patients have primary cutaneous T‐cell lymphoma, and the remaining one‐third have primary cutaneous B‐cell lymphoma. Over the years, tremendous progress has been made regarding the diagnostics and classification of cutaneous lymphomas. An exact classification of cutaneous lymphomas is of great importance for the patient, because the different skin lymphomas have very different prognoses and require different therapeutic regimens.The basis for making a diagnosis is a clinical‐pathological correlation, including the use of several immunohistochemical markers and molecular biological methods. Treatment of cutaneous lymphoma is adapted to the type of lymphoma and disease stage. First‐line therapy consists of treatments that target the skin. Systemic treatment is used in advanced disease. Many targeted therapies have been introduced into routine clinical care in recent years. This review presents an up‐to‐date approach to the diagnosis and treatment of primary cutaneous lymphomas.
Title: Cutaneous lymphomas
Description:
SummaryPrimary cutaneous lymphomas are extranodal non‐Hodgkin lymphomas.
They are classified into the two main groups of primary cutaneous T‐ and B‐cell lymphomas.
Very rare cases are derived from NK or plasmacytoid dendritic cells.
The annual incidence is 1/100,000.
Two‐thirds of the patients have primary cutaneous T‐cell lymphoma, and the remaining one‐third have primary cutaneous B‐cell lymphoma.
Over the years, tremendous progress has been made regarding the diagnostics and classification of cutaneous lymphomas.
An exact classification of cutaneous lymphomas is of great importance for the patient, because the different skin lymphomas have very different prognoses and require different therapeutic regimens.
The basis for making a diagnosis is a clinical‐pathological correlation, including the use of several immunohistochemical markers and molecular biological methods.
Treatment of cutaneous lymphoma is adapted to the type of lymphoma and disease stage.
First‐line therapy consists of treatments that target the skin.
Systemic treatment is used in advanced disease.
Many targeted therapies have been introduced into routine clinical care in recent years.
This review presents an up‐to‐date approach to the diagnosis and treatment of primary cutaneous lymphomas.
Related Results
PKC beta II Expression in Lymphoid Malignancies.
PKC beta II Expression in Lymphoid Malignancies.
Abstract
Protein Kinase C (PKC) is an important enzyme family. Twelve different isozymes have been described, which are implicated in diverse cell responses. Recentl...
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Background
Cutaneous involvement is very common in systemic lupus erythematosus. We describe the prevalence and spectrum of lupus-specific (cutaneous lupus eryt...
Peripheral and cutaneous T-cell lymphomas in the United States: A 21-year mortality analysis (1999-2020).
Peripheral and cutaneous T-cell lymphomas in the United States: A 21-year mortality analysis (1999-2020).
e19055
Background:
Peripheral and cutaneous T-cell lymphomas (PTCL and CTCL) comprise of a vast variety of rare and heterogeneous subt...
Karyometric Comparison of Splenic and Gastric Marginal Zone Lymphomas
Karyometric Comparison of Splenic and Gastric Marginal Zone Lymphomas
Background: Marginal zone lymphomas are indolent B-cell lymphomas associated with autoimmunity and chronic inflammation. The two most frequent variants are mucosa associated lympho...
Epstein‐Barr virus (EBV) genomes and c‐myc oncogene in oral Burkitt's lymphomas
Epstein‐Barr virus (EBV) genomes and c‐myc oncogene in oral Burkitt's lymphomas
In addition to Burkitt's lymphomas, tentative evidence suggests the involvement of Epstein‐Barr virus (EBV) in malignant lymphomas of T‐cell origin. The c‐myc proto‐oncogene is str...
Non‐Hodgkin Lymphomas
Non‐Hodgkin Lymphomas
Abstract
Non‐Hodgkin lymphomas (NHLs) are malignant neoplasms of lymphoid cells, the predominant cells of the immune system. This term encompass...
LMP1 Expression of Esptein Baar Virus in Pediatric Lymphomas: A 06-Year Retrospective Series in Dakar
LMP1 Expression of Esptein Baar Virus in Pediatric Lymphomas: A 06-Year Retrospective Series in Dakar
Persistent Epstein Baar Virus (EBV) infection may be a perfect target for the treatment of EBV-associated lymphomas and improved patient outcomes. The aim of this work was to evalu...
Cell-Derived Microparticle (C-MP) Profiles in Lymphoproliferative Disorders: Association of Elevated Red Cell Microparticles (RMP) with Thrombosis.
Cell-Derived Microparticle (C-MP) Profiles in Lymphoproliferative Disorders: Association of Elevated Red Cell Microparticles (RMP) with Thrombosis.
Abstract
INTRODUCTION: Lymphoproliferative diseases embrace a variety of disorders including chronic lymphocytic leukemia (CLL), lymphomas and multiple myeloma (MM)....

